Skip to Content
Join the 'Leukemia' group to help and get support from people like you.

Leukemia News

Related terms: Cancer, Leukemia

Almost 90,000 Young American Adults Will Get Cancer This Year: Report

FRIDAY, Sept. 18, 2020 – Nearly 90,000 Americans between 15 and 39 years of age will be diagnosed with cancer this year and more than 9,200 will die, a new report projects. One hematologist who...

FDA Approves Oral Treatment for Myelodysplastic Syndrome

WEDNESDAY, July 8, 2020 – The U.S. Food and Drug Administration has approved Inqovi (decitabine and cedazuridine) tablets, an oral outpatient treatment option for patients with myelodysplastic...

Child's Cancer Doesn't Raise Parents' Divorce Risk, Curb Plans for More Kids: Study

MONDAY, May 25, 2020 – Having a child with cancer doesn't appear to affect parents' risk of splitting up or their plans to have more kids. That's the conclusion of a Danish study that compared more...

FDA Approves Calquence for Adults with Chronic Lymphocytic Leukemia

21 November 2019 – AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved Calquence (acalabrutinib) for adult patients with chronic lymphocytic leukemia (CLL) or s...

Agios Announces FDA Approval of Tibsovo as Monotherapy for Newly Diagnosed Adult Patients with IDH1 Mutant Acute Myeloid Leukemia (AML) Not Eligible for Intensive Chemotherapy

CAMBRIDGE, Mass., May 02, 2019 (GLOBE NEWSWIRE) – Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced the U.S. Food...

FDA Approves Asparlas (calaspargase pegol-mknl) for Acute Lymphoblastic Leukemia (ALL)

On December 20, 2018, the Food and Drug Administration approved calaspargase pegol-mknl (Asparlas, Servier Pharmaceuticals LLC), an asparagine specific enzyme, as a component of a multi-agent...

FDA Medwatch Alert: FDA Warns That Symptoms of a Serious Condition Affecting the Blood Cells Are Not Being Recognized with the Leukemia Medicine Idhifa (enasidenib)

The U.S. Food and Drug Administration (FDA) is warning that signs and symptoms of a life-threatening side effect called differentiation syndrome are not being recognized in patients receiving the...

FDA Approves Xospata (gilteritinib) for Acute Myeloid Leukemia (AML) with a FLT3 Mutation

November 28, 2018 – The U.S. Food and Drug Administration today approved Xospata (gilteritinib) tablets for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia...

Genentech Announces FDA Grants Venclexta Accelerated Approval for People With Newly-Diagnosed Acute Myeloid Leukemia or Those Who Are Ineligible For Intensive Induction Chemotherapy

South San Francisco, CA – November 21, 2018 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has granted...

FDA Approves Daurismo (glasdegib) for Patients with Acute Myeloid Leukemia

November 21, 2018 – The U.S. Food and Drug Administration today approved Daurismo (glasdegib) tablets to be used in combination with low-dose cytarabine (LDAC), a type of chemotherapy, for the...

FDA Approves Copiktra (duvelisib) Capsules for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Follicular Lymphoma

BOSTON--(BUSINESS WIRE)--Sep. 24, 2018-- Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines to improve the survival and quality of...

FDA Approves Lumoxiti (moxetumomab pasudotox-tdfk) for Hairy Cell Leukemia

September 13, 2018 – The U.S. Food and Drug Administration today approved Lumoxiti (moxetumomab pasudotox-tdfk) injection for intravenous use for the treatment of adult patients with relapsed or...

FDA Approves Tibsovo (ivosidenib) for Relapsed or Refractory Acute Myeloid Leukemia with an IDH1 Mutation

July 20, 2018 – The U.S. Food and Drug Administration today approved Tibsovo (ivosidenib) tablets for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) who...

FDA Expands Approval of Blincyto (blinatumomab) to Treat Minimal Residual Disease-Positive B-Cell Precursor Acute Lymphoblastic Leukemia

March 29, 2018 – The U.S. Food and Drug Administration granted accelerated approval to Blincyto (blinatumomab) to treat adults and children with B-cell precursor acute lymphoblastic leukemia (ALL)...

Novartis Drug Tasigna Approved by FDA to Treat Children with Rare Form of Leukemia

Basel, March 22, 2018 - Novartis announced today that the US Food and Drug Administration (FDA) expanded the indication for Tasigna (nilotinib) to include treatment of first- and second-line...

Ask a Question

Want to post your own question to this support group? You'll need to first create an account with Drugs.com (or sign in to your existing account).

Further Information

Related Condition Support Groups

Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia, Hairy Cell Leukemia, Blood Disorders

Related Drug Support Groups

prednisone, triamcinolone, dexamethasone